(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 1.55% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Teva Pharmaceutical Industries's revenue in 2024 is $15,846,000,000.On average, 5 Wall Street analysts forecast TEVA's revenue for 2024 to be $17,741,247,700,622, with the lowest TEVA revenue forecast at $17,622,588,868,310, and the highest TEVA revenue forecast at $17,982,347,936,440. On average, 5 Wall Street analysts forecast TEVA's revenue for 2025 to be $18,227,416,845,057, with the lowest TEVA revenue forecast at $17,815,417,038,202, and the highest TEVA revenue forecast at $18,498,051,181,500.
In 2026, TEVA is forecast to generate $18,583,734,154,573 in revenue, with the lowest revenue forecast at $17,650,055,671,580 and the highest revenue forecast at $19,224,520,100,628.